Endo Health Solutions on Monday announced that its Qualitest subsidiary has completed the acquisition of privately-held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.
Endo Health Solutions on Tuesday announced that NuPathe has terminated its merger agreement. Endo received a $5 million termination fee from NuPathe.
Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.
Endo Health Solutions will acquire Canadian drug maker Paladin Labs for $1.6 billion, mostly in shares of stock, Endo said Tuesday.
A subsidiary of Endo Health Solutions is buying Boca Pharmacal for $225 million, Endo said Wednesday.
The Food and Drug Administration has approved a generic opioid painkiller made by Actavis, the drug maker said.
A ruling by the Food and Drug Administration means that generic versions of an opioid painkiller made by Endo Pharmaceuticals can stay on the market, drawing criticism from the drug maker.
A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.
The parent company of Endo Pharmaceuticals has changed its name, the company said.
Endo's parent company is looking to change its name and will integrate four of its operating units, the drug maker said Thursday.